NCT03960840 : Phase I, Open Label, Multicenter, Dose Escalation Study of CD19-specific CAR-T Cells in Adult Patients With CLL/SLL and DLBCL

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaChronic Lymphocytic Leukaemia,Diffuse Large Cell Lymphoma,Leukaemia,Lymphoma

Trial Overview Read MoreRead more

This phase I trial evaluates the safety and effectiveness of engineered CAR-T cells (CD19 targeted) alone for treatment of patients with diffuse large B-cell lymphoma and in combination with targeted therapy (ibrutinib) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
 

This trial is treating patients with chronic lymphocytic leukaemia, small lymphocytic lymphoma and diffuse large B-cell lymphoma.

This is a systemic treatment.

You may be able to join this trial if:

  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase I, Open Label, Multicenter, Dose Escalation Study of CD19-specific CAR-T Cells in Adult Patients With CLL/SLL and DLBCL

Commercial Sponsor

Novartis Pharmaceuticals

Summary

Patients eligible for this trial will receive a single infusion of engineered CAR-T cells and daily doses of ibrutinib for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, or a single infusion of engineered CAR-T cells for treatment of diffuse large B-cell lymphoma.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next